These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 3121334)

  • 1. Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial.
    Serruys PW; Arnold AE; Brower RW; de Bono DP; Bokslag M; Lubsen J; Reiber JH; Rutsch WR; Uebis R; Vahanian A
    Eur Heart J; 1987 Nov; 8(11):1172-81. PubMed ID: 3121334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
    Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up.
    Schmidt WG; Uebis R; von Essen R; Effert S; Erbel R; Meyer J; Rutsch W; Schartl M; Schmutzler H
    Eur Heart J; 1987 Nov; 8(11):1182-8. PubMed ID: 3121335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
    Verstraete M; Arnold AE; Brower RW; Collen D; de Bono DP; De Zwaan C; Erbel R; Hillis WS; Lennane RJ; Lubsen J
    Am J Cardiol; 1987 Aug; 60(4):231-7. PubMed ID: 3113222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
    Haq A; Morgan CD; Wilson RF; Daly PA; Baigrie RS; White CW; Roberts R; Gent M; Armstrong PW
    Am J Cardiol; 1993 Aug; 72(5):379-83. PubMed ID: 8352178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
    Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
    N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
    Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
    Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
    Popma JJ; Califf RM; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Stump D; Woodlief L
    J Am Coll Cardiol; 1992 Nov; 20(6):1305-12. PubMed ID: 1430679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.
    Jang IK; Vanhaecke J; De Geest H; Verstraete M; Collen D; Van de Werf F
    J Am Coll Cardiol; 1986 Dec; 8(6):1455-60. PubMed ID: 3097099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
    Rapold HJ; Kuemmerli H; Weiss M; Baur H; Haeberli A
    Circulation; 1989 May; 79(5):980-9. PubMed ID: 2496939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
    Langer A; Minkowitz J; Dorian P; Casella L; Harris L; Morgan CD; Armstrong PW
    J Am Coll Cardiol; 1992 Nov; 20(6):1313-7. PubMed ID: 1430680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.
    Topol EJ; George BS; Kereiakes DJ; Stump DC; Candela RJ; Abbottsmith CW; Aronson L; Pickel A; Boswick JM; Lee KL
    Circulation; 1989 Feb; 79(2):281-6. PubMed ID: 2492454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis.
    Van Lierde J; De Geest H; Verstraete M; Van de Werf F
    J Am Coll Cardiol; 1990 Dec; 16(7):1545-9. PubMed ID: 2123904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial.
    Topol EJ; Califf RM; Kereiakes DJ; George BS
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):65B-74B. PubMed ID: 2959716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction.
    Topol EJ; O'Neill WW; Langburd AB; Walton JA; Bourdillon PD; Bates ER; Grines CL; Schork AM; Kline E; Pitt B
    Circulation; 1987 Feb; 75(2):420-8. PubMed ID: 2948735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction].
    Gao R
    Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Aug; 19(4):228-30, 267-8. PubMed ID: 1813288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct].
    Bleifeld W; Verstraete M; Brower RW; Collen D; Dunning AJ; Lubsen J; Michel PL; Schofer J; Vanhaecke J; Van de Werf F
    Klin Wochenschr; 1988; 66 Suppl 12():86-92. PubMed ID: 3126349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
    Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.